PV Bulletin

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Swissmedic introduces a comprehensive checklist aimed at enhancing compliance with medical device vigilance standards in Swiss hospitals.

Primary source: Medical devices

PV Impact Brief

Urgency: HighConfidence: high

What changed

The introduction of a formal checklist tool for hospital inspections regarding materiovigilance, enhancing standards for incident reporting and vigilance roles.

Why it matters

The checklist establishes a framework for hospitals and associated stakeholders to ensure vigilance compliance, thus improving patient safety and regulatory adherence in the handling of medical devices.

Action needed

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Relevant for
Regulatory Intelligence LeadPV Quality Lead
Processes impacted
Inspection Readiness
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Checklist
Policy status
effective
Publication date
2026-07-17
Policy change
Swissmedic has published a new checklist for the inspection of materiovigilance (medical device vigilance) systems in hospitals. The tool is intended to help hospital facilities perform gap analyses and ensure compliance with GPMV-Spital requirements.

Key changes

Introduction of a formal checklist tool for hospital materiovigilance inspections, focusing on the reporting of incidents and the role of the vigilance contact person.

Affected workflows

Inspection Readiness

Responsible groups

Quality AssuranceComplianceMedical Device Safety

PV impact

Updates the inspection framework for medical device vigilance in Switzerland; hospitals and potentially associated MAH stakeholders should use the checklist to ensure incident reporting compliance.

View regulator source

Source document details

Exact policy details

Applicable Legislation
The health facility identifies and applies relevant laws and regulations for its operations.
Applies to: All healthcare facilities conducting medical device vigilance
1.3.1 · p. 1 · High · Source
Quality Management Responsibility
The management is responsible for implementing regulatory requirements regarding vigilance processes.
Applies to: Healthcare facility management
3.1, 3.3 · p. 1 · High · Source
Retention Period for Records
Documents related to materiovigilance must be retained for at least 15 years.
Applies to: All medical device documentation
3.7, 6.1, 6.10, 8.5 · p. 1 · High · Source
Notification of Serious Incidents
Serious incidents must be reported within 2, 10, or 15 days depending on the severity.
Applies to: Healthcare facilities reporting serious incidents
6.1, 6.6 · p. 1 · High · Source
Vigilance Contact Person
A vigilance contact person must be appointed and reported to Swissmedic.
Applies to: Every healthcare facility
3.3.2 · p. 1 · High · Source

Evidence and confidence

Confidence: highSource updated: Jul 17, 2026

Full briefing

Practical implication

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Swissmedic has published a checklist to assist healthcare facilities in Switzerland with evaluating their compliance with medical device vigilance (materiovigilance) requirements. This checklist is designed to help identify gaps in adherence to the GPMV-Spital standards and is crucial for ensuring proper incident reporting mechanisms are in place.

What changed: The introduction of a formal checklist tool for hospital inspections regarding materiovigilance, enhancing standards for incident reporting and vigilance roles.

Why it matters: The checklist establishes a framework for hospitals and associated stakeholders to ensure vigilance compliance, thus improving patient safety and regulatory adherence in the handling of medical devices.

Practical implication: Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

View original source

Published from the Firecrawl policy change extraction pipeline.

Related updates for your role

publicFDA · USA · Updated Aug 28, 2026

FDA Approves Mimrylo for Polycythemia Vera Treatment

Urgency: High

Patients will be treated with an initial dose of 19 mg of Mimrylo, administered weekly, with careful monitoring to maintain hematocrit levels below 45%. The operation of post-marketing surveillance will be affected due to the introduction of this new drug.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Labeling Lead
verifiedRegulatory action: Latest
Read impact briefarrow_forward
publicMHRA · UK · Updated Aug 28, 2026

Record Ketamine Seizures Indicate Safety Concerns

Urgency: High

Monitor and evaluate the drug misuse trends and health impacts associated with ketamine, focusing on the increase in seizures as part of public health and law enforcement strategies.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEMA · European Union · Updated Aug 28, 2026

PSUSA/00001088/202512 - Safety Update Amendments for Dimenhydrinate

Urgency: High

Implement the updated product information by November 5, 2026, ensuring that all labeling and documentation includes the new warnings and risk profiles.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency · European Union · Updated Aug 28, 2026

Choline Salicylate PSUSA/00000732/202512 - Safety Update Assessment

Urgency: High

Implement new labeling requirements for choline salicylate products by November 5, 2026, including specific warnings as outlined.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward